telaprevir


Also found in: Medical, Wikipedia.
Related to telaprevir: sofosbuvir
Translations

telaprevir

n telaprevir m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Frohlich was vice president of business development at Arbutus Biopharma, and prior to that worked internationally at Johnson & Johnson and Merck in various roles leading commercial strategy across all stages of product development including the global launches of INCIVO (telaprevir) and STELARA (ustekinumab).
Just before the ultimate current advancements of remedies for six primary genotypes and subdivisions of HCV, various problematic standards of care (SOC) with negligible sustained virologic response (SVR) were accessible as distinct consolidation of pegylated alpha interferon, ribavirin, interferon, boceprevir and telaprevir; nonetheless, above mentioned included different poisonous as well as unfavourable reactions, with meagre sustainability [5-9].
Earlier, he was medical director at Vertex and served as a medical lead on the anti-HCV protease inhibitor, telaprevir (INCIVEK), and served as the Vertex Clinical Lead in the Joint Strategic Alliance Team with Janssen Pharmaceutical.
Pyrazinamide (PZ) has been used over the years as the first and second line anti-tuberculosis agent [3], Telaprevir agent for treating Hepatitis C [4], Oltiprazm, a schistosomicidal and tumor preventing agent [5, 6] and Bortezomib, used against Multiple Myweloma [7, 8].
Management took a significant step forward with the introduction in 2012 of the first two protease inhibitors, boceprevir and telaprevir. [18] These were oral add-on therapies to PEG-interferon and ribavirin and significantly enhanced SVR rates.
Previous HCV treatment with IFN or peginterferon (PEG) associated with ribavirin (RIB) was recorded for 459 (45.8%) patients, and 41 (4.1%) patients had received PEG and RIB associated with a first-generation protease inhibitor (boceprevir or telaprevir); the remaining patients (50.1%) had not been previously treated.
Telaprevir and boceprevir are first generation NS3/4A PIs approved for use in combination with pegIFN+R in genotype 1 HCV infection.
First-generation protease inhibiters include telaprevir (Incivek[R]) and boceprevir (Victrelis[R]).
The high quantity of drugs for the treatment of chronic hepatitis C (boceprevir, telaprevir, sofosbuvir, daclatasvir and simeprevir) and for infections due to HIV (darunavir, dolutegravir sodic, maraviroc, and raltegravir) incorporated in the period were cases that stood out.
They found that annual treatment rates more than doubled from 2,726 to 6,679 patients when pegylated interferon was introduced, declined for a while and then rose modestly to 4,900 patients when boceprevir and telaprevir were introduced, declined again to an all-time low of 2,609 and then rebounded to 9,180 patients when sofosbuvir and simeprevir were introduced, and finally skyrocketed to 31,028 patients when ledipasvir/ sofosbuvir and paritaprevir/ritonavir/ombitasvir/dasabuvir were introduced.
Similarly in Phase III clinical trials using protease inhibitors boceprevir and telaprevir gender had no impact on SVR rate23.